# Justin Renz

Type: Person

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/justin-renz
Canonical HTML page: https://getfinancebrief.com/entity/justin-renz

## Timeline

- **2026-03-08**: Earnings Previews — Seeking Alpha releases Q4 2025 previews for both Voyager and Zevra.
- **2026-03-05**: CFO Appointment — Zevra Therapeutics names Justin Renz as Chief Financial Officer.
- **2025-Q3**: Voyager Partnership Update — Voyager reports progress on TRACER platform milestones with Novartis.
- **2024-Q4**: Miplyffa Approval — Zevra receives FDA approval for arimoclomol in NPC.

## Recent coverage (1 stories)

### Biotech Earnings Preview: Voyager and Zevra Face Critical Q4 Milestones
2026-03-08 22:55:45 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Voyager Technologies and Zevra Therapeutics are set to report Q4 2025 results, highlighting a pivotal shift from clinical development to commercial execution and platform validation. Investors are focused on Zevra's Miplyffa launch trajectory and Voyager's CNS-focused partnership revenue.
Full story: https://getfinancebrief.com/story/voyager-zevra-q4-2025-earnings-preview

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.